Autonomix Medical (AMIX) Registration filing summary

Company overview and business model

• Development-stage medical device company focused on technologies for sensing and treating nervous system disorders, initially targeting pain management in pancreatic cancer patients.

• Proprietary catheter-based microchip array platform claims 3,000x greater sensitivity than nearest competitor, with potential applications in chronic pain, hypertension, cardiovascular, and other nerve-related disorders.

• Technology demonstrated successful nerve signal detection and ablation in animal models; human trials and pivotal clinical studies are planned for commercial launch.

Financial performance and metrics

• As of February 24, 2025, market value of public float was $6.4 million, with 2,462,983 shares outstanding and 1,988,093 held by non-affiliates.

• Net tangible book value as of December 31, 2024, was $9.7 million ($3.94/share); pro forma as adjusted after offering would be $3.35/share.

• November 2024 public offering raised approximately $10 million in gross proceeds.

• Audit opinion includes substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Proceeds from offerings will be used for clinical and preclinical programs, R&D, working capital, debt repayment, and potential acquisitions.

• ATM offering proceeds specifically allocated for working capital and general corporate purposes, with management retaining broad discretion.